Overview
The 70-Gene Signature (MammaPrint) is a genomic assay designed to classify early-stage breast cancer patients into low-risk or high-risk categories for distant recurrence. According to the document (page 2), this test was developed to assess the first 5 years after diagnosis, a period in which recurrence risk is most critical. The genes included in MammaPrint capture the six hallmarks of cancer-related biology—as stated on page 3—reflecting mechanisms linked to tumor progression, invasion, metastasis, apoptosis regulation, angiogenesis, and cellular growth.
The test produces a MammaPrint Index (MPI) ranging from –1.000 to +1.000, where positive scores indicate lower risk and negative scores predict higher metastatic potential (page 6). MPI categorization (page 7) includes Ultra-Low Risk, Low Risk, Borderline, and High Risk, each with associated survival outcomes and treatment implications.
The document also highlights expanded applications beyond breast cancer, including advanced cervical cancer outcome prediction (pages 4 and 17). Overall, MammaPrint guides adjuvant therapy decisions, improves individualized treatment planning, and supports shared decision-making (page 13).
Symptoms
MammaPrint is a molecular test, not a medical condition; thus, it does not produce symptoms. Instead, symptoms relate to the clinical presentations that prompt ordering the test.
Symptoms Suggesting Breast Cancer
These symptoms often lead to a biopsy, after which the tissue may be used for the MammaPrint assay (page 9):
- Breast lump or palpable mass
- Skin changes, nipple discharge, or thickening
- Pain or discomfort in the breast
- Imaging abnormalities requiring tissue sampling
Symptoms Suggesting Higher Recurrence Risk
Following breast cancer diagnosis, certain features or changes may signal a need for genomic stratification:
- Persistent fatigue
- Local breast changes after surgery
- Suspicious findings on follow-up imaging
- New systemic symptoms, such as bone pain or weight changes, warrant recurrence risk evaluation
Symptoms Related to Cervical Cancer Progression
As shown in the predictive model on page 17, patients with advanced cervical cancer may have symptoms such as pelvic pain, bleeding, or systemic discomfort. MammaPrint helps classify patients into therapy-responsive vs. non-responsive groups.
Causes
Here, “causes” refer to the biological and clinical reasons that make the 70-Gene Signature necessary.
1. Molecular Diversity in Tumors
Breast cancer is biologically heterogeneous. The listed genes (page 5) represent categories including:
- Invasion & metastasis
- Cell cycle & proliferation
- Apoptosis evasion
- Sustained angiogenesis
- Anti-growth signaling insensitivity
Variations in these pathways cause unpredictable clinical behavior that requires genomic risk assessment.
2. Need for Accurate Recurrence Prediction
Pathology alone cannot reliably predict 5-year recurrence. The MammaPrint Index addresses this gap (page 6).
3. Decision Support for Chemotherapy
Clinical risk may appear high, but genomic risk may be low (page 16), preventing unnecessary chemotherapy.
4. Tumor Biology Driving Metastasis
High-risk tumors exhibit aggressive expression patterns reflected in the MPI ranges (page 8).
5. Need for Personalized Treatment
MammaPrint integrates tumor biology with clinical evaluation to enable individualized decisions (page 13).
Risk Factors
Risk factors here refer to patient profiles where MammaPrint is particularly useful.
1. Early Breast Cancer Patients (Primary Indication)
According to page 4, this includes:
- Tumor size ≤ 5 cm
- Axillary node status 0–3 positive nodes
- Invasive carcinoma
- Patients considering adjuvant chemotherapy
- Those with intermediate clinical or pathological risk
2. Patients With Ambiguous Recurrence Risk
Borderline or unclear pathology may require genomic clarification.
3. Hormone Receptor–Positive Patients
Ultra-low and low-risk MPI categories are commonly applied to hormone receptor–positive cases (page 7).
4. Patients With High Clinical Risk but Uncertain Genomic Profile
As noted on page 16, clinically high-risk patients may still be genomically low-risk.
5. Advanced Cervical Cancer Patients
Page 17 depicts gene-expression-based prediction of therapy response.
Prevention
While MammaPrint does not prevent cancer, it prevents over-treatment, under-treatment, and misclassification through structured genomic interpretation.
1. Correct Use of Risk Categories
MPI categories help determine whether chemotherapy is unnecessary or essential (page 8).
2. Integrate Test Results With Clinical Parameters
The test is not stand-alone and must be paired with clinical and imaging findings (page 15).
3. Ensure Proper Sample Collection and Handling
- Tissue must be collected via biopsy, lumpectomy, or mastectomy (page 9).
- It must be fixed in 10% formalin and transported at room temperature for RNA analysis (page 11).
4. Avoid Using Metastatic Tissue
The document clearly states that metastatic tissue is not suitable for MammaPrint (page 9).
5. Use Validated Populations Only
Interpretation is limited outside validated groups, mainly breast cancer patients (page 15).
6. Support Early Identification of High-Risk Patients
The advantages listed on page 14 highlight enhanced early identification, improving long-term outcomes.
